Duality Advisers’s NovoCure NVCR Stock Holding History

Duality Advisers’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-54,526	Closed	-$2.26M	–	668
2023 Q2	$2.26M	Buy	54,526 +38,540	+241%	+$2.39M	0.28%	132
2023 Q1	$961K	Sell	15,986 -14,994	-48%	-$1.2M	0.11%	307
2022 Q4	$2.27M	Buy	30,980 +24,683	+392%	+$1.86M	0.26%	122
2022 Q3	$478K	Sell	6,297 -25,534	-80%	-$1.99M	0.05%	427
2022 Q2	$2.21M	Buy	+31,831	New	+$2.4M	0.22%	177
2022 Q1	–	Sell	-15,466	Closed	-$1.16M	–	771
2021 Q4	$1.16M	Sell	15,466 -648	-4%	-$65K	0.13%	265
2021 Q3	$1.87M	Buy	16,114 +10,002	+164%	+$1.51M	0.14%	253
2021 Q2	$1.36M	Buy	6,112 +1,179	+24%	+$229K	0.12%	284
2021 Q1	$652K	Buy	+4,933	New	+$780K	0.06%	413

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Duality Advisers's NVCR Position: Q3 2023 in Review

Duality Advisers sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 54,526 shares — an estimated $2.26M sold.

Duality Advisers first reported a position in NVCR in Q1 2021 and held it in 9 quarters. The position peaked at $2.27M in Q4 2022. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

Duality Advisers reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
Duality Advisers sold 54,526 NovoCure shares in Q3 2023, an estimated $2.26M.
Duality Advisers first reported a position in NovoCure in Q1 2021 and held it in 9 quarters.
Duality Advisers's NovoCure position peaked at $2.27M in Q4 2022.
226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Duality Advisers's 13F filing for Q3 2023, filed 2 Nov 2023.